Adding rifampin to antibiotics after DAIR for staphylococcal periprosthetic joint infection
Official title: The Efficacy and Complications of Rifampin-combined Antibiotic Therapy for Staphylococcal Periprosthetic Joint Infections（PJI）: A Multicenter, Randomized Controlled Trial
Run by First Affiliated Hospital of Fujian Medical University · NCT07313215 · Data updated 2026-11-12
This trial tests whether giving rifampicin in addition to standard antibiotics for adults with staphylococcal periprosthetic joint infection after DAIR improves long-term infection control.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 428 (estimated) |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Status | Recruiting |
| Started | November 13, 2025 |
| Main results expected | June 30, 2027 |
| Study ends | December 18, 2027 |
| Registry record updated | December 31, 2025 |
| Trial ID | NCT07313215 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults under 80 with MSIS-confirmed PJI caused by Staphylococcus who have undergone DAIR, have sufficient clinical data, no major immunosuppression or organ dysfunction, and can consent and complete follow-up.
✕Probably not a fit
Patients with non-staphylococcal or mixed infections, chronic nonrelated inflammatory conditions, significant liver or kidney dysfunction, severe immunodeficiency, or short expected survival are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, randomized multicenter trial enrolling patients with Staphylococcus-confirmed periprosthetic joint infection treated with debridement, antibiotics, and implant retention (DAIR). After 1–2 weeks of intravenous antibiotics, participants are randomized to receive either a three-month oral antibiotic regimen (fluoroquinolones or linezolid guided by culture) alone or the same regimen plus rifampicin for three months. Outcomes include infection control rate with at least two years of follow-up, recurrence, inflammatory markers, prosthesis function recovery, and drug-related adverse events. The trial follows CONSORT reporting standards and uses a unified data recording system across sites.
Why it matters
Potential benefit: If successful, adding rifampicin could lower infection recurrence and improve prosthesis retention and function in staphylococcal PJI patients.
How similar studies have gone: Previous randomized and observational studies have suggested rifampin can improve outcomes in staphylococcal prosthetic joint infections when paired with effective companion antibiotics, but findings have varied and optimal regimens remain uncertain.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Diagnosed as PJI according to the MSIS criteria
* The pathogenic bacteria were identified as Staphylococcus through microbial culture and drug sensitivity tests were conducted
* There are complete clinical data ④ Age under 80 years old, without serious complications or immunosuppressive status ⑤ The patient voluntarily participated in this study and was physically and mentally tolerant of the treatment process and various tests in this study. They have signed the informed consent form and passed the review of the ethics committees of all hospitals participating in this study
Exclusion Criteria:
* Those with chronic inflammation in other parts of the body before the operation
* Non-staphylococcal infection or mixed infection
* The patient has other diseases that may affect the outcome, such as immune deficiency or liver and kidney dysfunction ④ Those with an expected lifespan of less than half a year ⑤ The researcher determined that the patient no longer met the criteria of this study due to compliance issues
Where it's running
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China Recruiting
Study contacts
- Study coordinator: Xinyu Fang, MD
- Email: fangxinyu0417@fjmu.edu.cn
- Phone: 86+18084768503
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Optimizing skin cleansing before shoulder surgery
This study is testing whether using different pressure techniques to apply a skin cleanser can help reduce bacteria on the skin before shoulder surgery.
-
REMEDY SPECTRUM intramedullary spacer nail for ankle infections
This trial will test the REMEDY SPECTRUM intramedullary spacer nail in adults with ankle-related infections to see if it is safe and helps treat the infection.
-
Comparing biopsy and aspiration for diagnosing joint infections in shoulder and elbow surgeries
This study is testing whether using a needle to take fluid from the joint or doing a surgical biopsy is better for diagnosing infections in patients having shoulder or elbow surgeries.
-
Reducing infections after total joint replacement surgery
This study is testing if using special antiseptic solutions and antibiotics can help prevent infections in adults having total joint replacement surgery.
-
Evaluating antibiotic treatment after joint revision surgery for infection
This study is testing if a specific antibiotic treatment after joint revision surgery for infection can help patients recover better and prevent further infections.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.